Table 1.
Baseline characteristics
| Overall N = 48 | Esophagus N = 17 | Duodenum N = 13 | Colorectum N = 18 | |
|---|---|---|---|---|
| Age in years, median (IQR) | 68.5 (55.3–73.0) | 70.0 (61.0–74.5) | 53.0 (46.0–71.0) | 69.5 (62.0–73.3) |
| Sex (male), n (%) | 29 (60.4) | 12 (70.6) | 8 (61.5) | 9 (50.0) |
| BMI, mean (SD) | 26.9 (3.8) | 26.7 (3.6) | 28.4 (3.8) | 25.8 (3.9) |
| ASA, n (%) | ||||
| 1 | 3 (6.3) | – | 2 (15.4) | 1 (5.6) |
| 2 | 31 (64.6) | 10 (58.8) | 9 (69.2) | 12 (66.7) |
| 3 | 12 (25.0) | 6 (35.3) | 1 (7.7) | 5 (27.8) |
| 4 | 2 (4.2) | 1 (5.9) | 1 (7.7) | – |
| Smoking, n (%) | 11 (22.9) | 5 (29.4) | – | 6 (33.3) |
| Regular alcohol intake, n (%) | 20 (41.7) | 11 (64.7) | 1 (7.7) | 8 (44.4) |
| Cardiovascular comorbidity, n (%) | 24 (50.0) | 13 (76.5) | 4 (30.8) | 7 (38.9) |
| Hypertension | 10 (20.8) | 6 (35.3) | 1 (7.7) | 3 (16.7) |
| Antithrombotic medication, n (%) | ||||
| No | 31 (64.6) | 10 (58.8) | 11 (84.6) | 10 (55.6) |
| Platelet inhibitors | 8 (16.7) | 4 (23.5) | 1 (7.7) | 3 (16.7) |
| Vit K antagonists | 6 (12.5) | 2 (11.8) | 1 (7.7) | 3 (16.7) |
| Combination therapya | 1 (2.1) | 1 (5.9) | – | – |
| DOAC/NOAC | 2 (4.2) | 0 | – | 2 (11.1) |
| Portal hypertension, n (%) | – | – | – | – |
IQR interquartile range, BMI body mass index, SD standard deviation, ASA America Society of Anesthesiologists, Vit K antagonists vitamin K antagonists, DOAC/NOAC direct oral anticoagulants/new oral anticoagulants
aCombination therapy defined as concurrent use of aspirin and acenocoumarin